Literature DB >> 2285275

In vitro selection of resistant Helicobacter pylori.

C E Haas1, D E Nix, J J Schentag.   

Abstract

Four strains of Helicobacter pylori were subjected to an in vitro serial passage technique to compare the propensity of the organisms to develop resistance to seven classes of antibacterial agents. The passages were made on serially doubling concentrations of antibacterial agents incorporated into agar starting at one-half the base-line MIC. The frequency of spontaneous resistance was also determined for each strain at four and eight times the MIC of each antibacterial agent. Strains resistant to ciprofloxacin, metronidazole, erythromycin, and tobramycin were isolated. The experiments failed to select organisms resistant to bismuth subsalicylate, furazolidone, or amoxicillin, although the MIC of amoxicillin was increased 4- to 16-fold. With the exception of erythromycin, organisms with the selected resistance were stable after at least three passages on antibacterial agent-free medium. Spontaneous resistance rates were generally of a low magnitude and were not predictive of the serial passage results.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2285275      PMCID: PMC171897          DOI: 10.1128/AAC.34.9.1637

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.

Authors:  C A McNulty; J C Gearty; B Crump; M Davis; I A Donovan; V Melikian; D M Lister; R Wise
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

2.  In vivo susceptibility of Campylobacter pylori.

Authors:  D Y Graham; P D Klein; A R Opekun; K E Smith; R R Polasani; D J Evans; D G Evans; L C Alpert; P A Michaletz; H H Yoshimura
Journal:  Am J Gastroenterol       Date:  1989-03       Impact factor: 10.864

3.  Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

Authors:  E A Rauws; W Langenberg; H J Houthoff; H C Zanen; G N Tytgat
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

4.  Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori.

Authors:  A E Simor; S Ferro; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

5.  Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents.

Authors:  T Lambert; F Mégraud; G Gerbaud; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

Review 6.  Chemotherapeutic properties of prominent nitrofurans.

Authors:  R E Chamberlain
Journal:  J Antimicrob Chemother       Date:  1976-12       Impact factor: 5.790

Review 7.  The clinical significance of Campylobacter pylori.

Authors:  C P Dooley; H Cohen
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

8.  Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with amoxycillin.

Authors:  Y Glupczynski; A Burette; M Labbe; C Deprez; M De Reuck; M Deltenre
Journal:  Am J Gastroenterol       Date:  1988-04       Impact factor: 10.864

9.  Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study.

Authors:  J G Coghlan; D Gilligan; H Humphries; D McKenna; C Dooley; E Sweeney; C Keane; C O'Morain
Journal:  Lancet       Date:  1987-11-14       Impact factor: 79.321

10.  Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.

Authors:  J H Tenney; R W Maack; G R Chippendale
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

View more
  37 in total

1.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

2.  Susceptibility of Helicobacter pylori to metronidazole.

Authors:  M López-Brea; E Martín; C López-Lavid; J C Sanz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

3.  Search for novel candidate mutations for metronidazole resistance in Helicobacter pylori using next-generation sequencing.

Authors:  Tran Thanh Binh; Rumiko Suzuki; Tran Thi Huyen Trang; Dong Hyeon Kwon; Yoshio Yamaoka
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

Review 4.  "Rescue" regimens after Helicobacter pylori treatment failure.

Authors:  Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

5.  Role of metronidazole resistance in therapy of Helicobacter pylori infections.

Authors:  H Rautelin; K Seppälä; O V Renkonen; U Vainio; T U Kosunen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

6.  Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice.

Authors:  P J Jenks; R L Ferrero; J Tankovic; J M Thiberge; A Labigne
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

7.  Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains.

Authors:  A A van Zwet; J C Thijs; B de Graaf
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  The population dynamics of antimicrobial chemotherapy.

Authors:  M Lipsitch; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 9.  Third-line rescue therapy for Helicobacter pylori infection.

Authors:  Rossella Cianci; Massimo Montalto; Franco Pandolfi; Giovan-Battista Gasbarrini; Giovanni Cammarota
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

10.  In vitro activity of metronidazole against Helicobacter pylori as determined by agar dilution and agar diffusion.

Authors:  C C Knapp; M D Ludwig; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.